Non-dialysis patients with advanced CKD diagnosed with renal malignancies grapple with the dual threat of renal failure and cancer progression. When choosing between functional or oncologic risks, many patients will ask about renal transplantation. Discussions of this option are complicated by statistical realities: According to UNOS, of nearly 1 million solid organ transplants performed over…
Investigators observed no differences in surgery time, blood loss, and hospital stay, with deferred vs upfront cytoreductive nephrectomy.
Cytoreductive nephrectomy (CN) by itself for metastatic renal cell carcinoma is associated with a 43% decreased risk of death compared with CN plus targeted therapy.
In a population-based study, PN was associated with improved cancer-specific survival by 56%.
In a meta-analysis, partial and radical nephrectomy were associated with similar long-term overall survival, but cancer-specific survival was better with radical nephrectomy.
The expression of interferon-related genes in tumor specimens was associated with response to neoadjuvant immune checkpoint inhibitor-based therapy.
Outside of clinical trials, targeted therapies for advanced renal cell carcinoma in Medicare patients are associated with modest survival advantages over non-targeted therapies.
As understanding of cancer improves, drug development could become accelerated, necessitating a means for determining whether a drug is actually effective.
Efficacy benefits of pembrolizumab plus axitinib over sunitinib were also observed in patients with disease characterized by sarcomatoid features.
Nivolumab plus ipilimumab, both checkpoint inhibitors, exhibit promising anti-tumor activity in patients with advanced renal cell carcinoma with brain metastases, researchers report.
